Arshad M, Azad A, Chan P, Vigneswara V, Feldinger K, Nafi S
Br J Cancer. 2024; 130(12):1990-2002.
PMID: 38600326
PMC: 11182766.
DOI: 10.1038/s41416-024-02665-z.
Mierke C
Front Cell Dev Biol. 2023; 11:1130823.
PMID: 36910158
PMC: 9995898.
DOI: 10.3389/fcell.2023.1130823.
Xu J, Wang Y, Jiang J, Yin C, Shi B
J Transl Med. 2023; 21(1):56.
PMID: 36717944
PMC: 9885678.
DOI: 10.1186/s12967-023-03913-1.
Arai J, Otoyama Y, Nozawa H, Kato N, Yoshida H
Oncogene. 2022; 42(8):549-558.
PMID: 36572816
PMC: 9937921.
DOI: 10.1038/s41388-022-02583-5.
Li M, Ning Y, Tse G, Saguner A, Wei M, Day J
ESC Heart Fail. 2022; 9(6):3768-3784.
PMID: 35920287
PMC: 9773734.
DOI: 10.1002/ehf2.14089.
Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis K, George A, Wozniak A, Bigogno C, Chow B, Hanrahan J
Cancer Genomics Proteomics. 2022; 19(4):390-414.
PMID: 35732328
PMC: 9247880.
DOI: 10.21873/cgp.20328.
Effect of type 2 diabetes on A disintegrin and metalloprotease 10.
Lam S, Shiu S, Wong Y, Choon-Beng Tan K
J Diabetes. 2022; 14(6):394-400.
PMID: 35705192
PMC: 9366558.
DOI: 10.1111/1753-0407.13287.
Extracellular Matrix Enzymes and Immune Cell Biology.
McMahon M, Ye S, Pedrina J, Dlugolenski D, Stambas J
Front Mol Biosci. 2021; 8:703868.
PMID: 34527702
PMC: 8436118.
DOI: 10.3389/fmolb.2021.703868.
Simultaneous detection of multiple proteases using a non-array nanopore platform.
Chen X, Zhang Y, Guan X
Nanoscale. 2021; 13(32):13658-13664.
PMID: 34477641
PMC: 8485758.
DOI: 10.1039/d1nr04085e.
Prognostic Significance of ADAM17 for Gastric Cancer Survival: A Meta-Analysis.
Ni P, Yu M, Zhang R, He M, Wang H, Chen S
Medicina (Kaunas). 2020; 56(7).
PMID: 32610677
PMC: 7404708.
DOI: 10.3390/medicina56070322.
Degradome of soluble ADAM10 and ADAM17 metalloproteases.
Scharfenberg F, Helbig A, Sammel M, Benzel J, Schlomann U, Peters F
Cell Mol Life Sci. 2019; 77(2):331-350.
PMID: 31209506
PMC: 11105009.
DOI: 10.1007/s00018-019-03184-4.
Protease activity as a prognostic factor for wound healing in venous leg ulcers.
Westby M, Dumville J, Stubbs N, Norman G, Wong J, Cullum N
Cochrane Database Syst Rev. 2018; 9:CD012841.
PMID: 30171767
PMC: 6513613.
DOI: 10.1002/14651858.CD012841.pub2.
The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.
Escalona R, Chan E, Kannourakis G, Findlay J, Ahmed N
Int J Mol Sci. 2018; 19(2).
PMID: 29393911
PMC: 5855672.
DOI: 10.3390/ijms19020450.
The ADAMs family of proteases as targets for the treatment of cancer.
Mullooly M, McGowan P, Crown J, Duffy M
Cancer Biol Ther. 2016; 17(8):870-80.
PMID: 27115328
PMC: 5004698.
DOI: 10.1080/15384047.2016.1177684.
Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
Caiazza F, McGowan P, Mullooly M, Murray A, Synnott N, ODonovan N
Br J Cancer. 2015; 112(12):1895-903.
PMID: 26010411
PMC: 4580380.
DOI: 10.1038/bjc.2015.163.
High-throughput protease activity cytometry reveals dose-dependent heterogeneity in PMA-mediated ADAM17 activation.
Wu L, Claas A, Sarkar A, Lauffenburger D, Han J
Integr Biol (Camb). 2015; 7(5):513-24.
PMID: 25832727
PMC: 4428935.
DOI: 10.1039/c5ib00019j.
ADAM10 and ADAM17: New players in trastuzumab tesistance.
Duffy M, Crown J, Mullooly M
Oncotarget. 2014; 5(22):10963-4.
PMID: 25460503
PMC: 4294375.
DOI: 10.18632/oncotarget.2794.
A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications.
Nyren-Erickson E, Jones J, Srivastava D, Mallik S
Biochim Biophys Acta. 2013; 1830(10):4445-55.
PMID: 23680494
PMC: 3740046.
DOI: 10.1016/j.bbagen.2013.05.011.
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
Ni S, Zhang J, Zhao W, Dong X, Wang J
Tumour Biol. 2013; 34(3):1813-8.
PMID: 23475633
DOI: 10.1007/s13277-013-0721-3.
Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10.
Prox J, Willenbrock M, Weber S, Lehmann T, Schmidt-Arras D, Schwanbeck R
Cell Mol Life Sci. 2012; 69(17):2919-32.
PMID: 22446748
PMC: 11114675.
DOI: 10.1007/s00018-012-0960-2.